Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
40
ELV Quote, Financials, Valuation and Earnings
Last price:
$343.53
Seasonality move
:
10.44%
Day range:
$342.54 - $346.86
52-week range:
$273.71 - $458.75
Dividend yield:
1.99%
P/E ratio:
14.04x
P/S ratio:
0.40x
P/B ratio:
1.74x
Volume:
458.3K
Avg. volume:
1.6M
1-year change:
-7.95%
Market cap:
$76.3B
Revenue:
$176.8B
EPS (TTM):
$24.45
Analysts' Opinion
-
Consensus RatingElevance Health, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $389.21, Elevance Health, Inc. has an estimated upside of 13.37% from its current price of $343.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $320.00 representing 100% downside risk from its current price of $343.30.
Fair Value
-
According to the consensus of 17 analysts, Elevance Health, Inc. has 13.37% upside to fair value with a price target of $389.21 per share.
ELV vs. S&P 500
-
Over the past 5 trading days, Elevance Health, Inc. has underperformed the S&P 500 by -2.17% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Elevance Health, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Elevance Health, Inc. has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Elevance Health, Inc. reported revenues of $50.7B.
Earnings Growth
-
Elevance Health, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Elevance Health, Inc. reported earnings per share of $5.32.
Enterprise value:
108.5B
EV / Invested capital:
1.42x
Price / LTM sales:
0.40x
EV / EBIT:
15.28x
EV / Revenue:
0.56x
PEG ratio (5yr expected):
9.29x
EV / Free cash flow:
28.81x
Price / Operating cash flow:
20.68x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
4.62%
Net Income Margin (TTM):
2.84%
Return On Equity:
12.81%
Return On Invested Capital:
7.52%
Operating Margin:
3.47%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $168.6B | $174B | $194.8B | $45.1B | $50.7B | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $8.8B | $9.2B | $8.5B | $1.7B | $1.8B | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | $25.13 | $27.43 | $24.45 | $4.36 | $5.32 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $51.9B | $55.6B | $61.2B | $62.8B | $63.8B | |
| Total Assets | $98.1B | $103B | $110.5B | $116.5B | $122.7B | |
| Current Liabilities | $35.2B | $41.3B | $43.3B | $42B | $40.9B | |
| Total Liabilities | $62.3B | $67B | $71.9B | $72.7B | $78.7B | |
| Total Equity | $35.8B | $36B | $38.5B | $43.9B | $44.1B | |
| Total Debt | $23.6B | $24.4B | $25.7B | $26.8B | $31.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.5B | $2.1B | $4.9B | $2.7B | $1.1B | |
| Cash From Investing | -$4.3B | -$4.6B | -$3.4B | -$401M | -$1.2B | |
| Cash From Financing | -$3.2B | -$609M | -$566M | -$915M | $243M | |
| Free Cash Flow | $8.2B | $871M | $3.8B | $2.3B | $775M | |
ELV
Sector
Market Cap
$76.3B
$28.1M
Price % of 52-Week High
74.83%
51.39%
Dividend Yield
1.99%
0%
Shareholder Yield
6.31%
-1.49%
1-Year Price Total Return
-7.95%
-17.13%
Beta (5-Year)
0.522
0.518
Dividend yield:
1.99%
Annualized payout:
$6.52
Payout ratio:
32.17%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$346.83
200-day SMA
Sell
Level
$355.31
Bollinger Bands (100)
Buy
Level
306.6 - 345.12
Chaikin Money Flow
Buy
Level
313.7M
20-day SMA
Buy
Level
$341.39
Relative Strength Index (RSI14)
Buy
Level
53.48
ADX Line
Buy
Level
11.15
Williams %R
Neutral
Level
-49.9259
50-day SMA
Buy
Level
$334.47
MACD (12, 26)
Buy
Level
4.07
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
147.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.9933)
Buy
CA Score
(Annual)
Level (-0.1905)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.9188)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Elevance Health, Inc. operates as a health company, which engages in improving lives and communities, and making healthcare simpler. It operates through the following segments: Health Benefits, CarelonRx, Carelon Services, and Corporate and Other. The Health Benefits segment offers a comprehensive suite of health plans and services to different customers. The CarelonRx segment markets and offers pharmacy services to affiliated health plan customers, as well as to external customers. The Carelon Services segment integrates physical, behavioral, pharmacy, and social services with the aim of delivering whole health affordably by offering a broad array of healthcare related services. The Corporate & Other segment includes businesses that do not individually meet the quantitative threshold for an operating segment. The company was founded in 1944 and is headquartered in Indianapolis, IN.
Stock Forecast FAQ
In the current month, ELV has received 9 Buy ratings 8 Hold ratings, and 0 Sell ratings. The ELV average analyst price target in the past 3 months is $389.21.
-
Where Will Elevance Health, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Elevance Health, Inc. share price will rise to $389.21 per share over the next 12 months.
-
What Do Analysts Say About Elevance Health, Inc.?
Analysts are divided on their view about Elevance Health, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Elevance Health, Inc. is a Sell and believe this share price will drop from its current level to $320.00.
-
What Is Elevance Health, Inc.'s Price Target?
The price target for Elevance Health, Inc. over the next 1-year time period is forecast to be $389.21 according to 17 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is ELV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Elevance Health, Inc. is a Buy. 9 of 17 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ELV?
You can purchase shares of Elevance Health, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Elevance Health, Inc. shares.
-
What Is The Elevance Health, Inc. Share Price Today?
Elevance Health, Inc. was last trading at $343.53 per share. This represents the most recent stock quote for Elevance Health, Inc.. Yesterday, Elevance Health, Inc. closed at $343.30 per share.
-
How To Buy Elevance Health, Inc. Stock Online?
In order to purchase Elevance Health, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ELV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ELV
Sector
P/E ratio
14.04x
23.89x
PEG ratio
9.29x
-0.01x
P/B ratio
1.74x
1.81x
Price / LTM sales
0.40x
1.59x
Growth Metrics
ELV
Sector
Revenue growth
12.33%
4.62%
Earnings growth
21.95%
11.06%
Revenue (5-year growth)
11.15%
6.5%
Earnings forecast
$4.94
-$0.21
Profitability
ELV
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
7.52%
-31.84%
Return on assets
4.62%
-27.96%
Return on equity
12.81%
-37.63%
Earnings Date
Last Earnings Date
Oct
21
Next Earnings Date
Jan
28
Estimated Next Earnings Date
Jan
20
Balance Sheet
ELV
Sector
Total cash
$33.9B
$26.4M
Short term investments
$25.2B
$25.7M
Total assets
$116.9B
$76.9M
Long term debt
$31.9B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
